Cipla rises on getting USFDA’s final nod for Lanreotide injection
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
https://t.me/InvestmentGuruIndiacom
Download Telegram App before Joining the Channel
Cipla is currently trading at Rs. 1457.80, up by 14.60 points or 1.01% from its previous closing of Rs. 1443.20 on the BSE.
The scrip opened at Rs. 1451.10 and has touched a high and low of Rs. 1467.10 and Rs. 1437.10 respectively. So far 71397 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1519.00 on 11-Mar-2024 and a 52 week low of Rs. 915.50 on 22-May-2023.
Last one week high and low of the scrip stood at Rs. 1467.10 and Rs. 1388.00 respectively. The current market cap of the company is Rs. 117539.88 crore.
The promoters holding in the company stood at 33.47%, while Institutions and Non-Institutions held 50.17% and 16.36% respectively.
Cipla and its wholly owned subsidiary Cipla USA Inc have received the final approval for its Abbreviated New Drug Application (ANDA) for Lanreotide Injection 120 mg/0.5 mL, 90 mg/0.3 mL, 60 mg/0.2 mL from the United States Food and Drug Administration (USFDA).
Cipla’s Lanreotide Injection is AP-rated therapeutic equivalent generic version of Somatuline Depot (lanreotide) Injection. Lanreotide Injection is supplied as 120 mg/0.5 mL, 90 mg/0.3 mL, 60 mg/0.2 mL single-dose, pre-filled, ready-toinject syringe. Cipla’s Lanreotide injection is indicated for the treatment of patients with Acromegaly and Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs).
According to IQVIA (IMS Health), Somatuline Depot (Lanreotide) had US sales of around $898 million for the 12-month period ending March 2024.
Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients.
